Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone
- Sponsor
- Amsterdam UMC, location VUmc
- Study ID
- NCT04392037
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Iberdomide plus low-dose cyclophosphamide and dexamethasone — DRUGIberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity
Study Details
Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Key Dates
- Start date
- Feb 17, 2021
- Status verified
- Mar 2025
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 60 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Iberdomide plus low-dose cyclophosphamide and dexamethasoneIberdomide 1.6mg on days 1-21 Low-dose Cyclophosphamide 50 mg on days 1-28 of each 28 day cycle Dexamethasone 40 mg once weekly (20 mg in patients aged \> 75 years)
Primary Outcome Measure
Progression free survival [ Time Frame: up to 5 years ]
Related Studies
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Family Study of Lymphoproliferative DisordersRecruiting · Mayo Clinic · Rochester, Minnesota
- Collection of Samples and Clinical Data From Patients With Amyloid DiseasesRecruiting · Boston Medical Center · Boston, Massachusetts
- Collection of Tissue Samples for Cancer ResearchRecruiting · National Cancer Institute (NCI) · Sacramento, California